Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 20,000 shares at $61.97 ($1.3M) on 2016-10-14, disclosed to the SEC on 2016-10-18.
Open-market sale of $1.3M RARE by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $61.97 | 6,515 | $404K | 32.0% |
| 2 | $63.06 | 9,340 | $589K | 46.7% |
| 3 | $64.41 | 2,345 | $151K | 12.0% |
| 4 | $64.78 | 1,800 | $117K | 9.3% |
| Total | $63.02 avg | 20,000 | $1.3M | 100% |
| Filing → |
| RARE | SELL | 2024-12-31 | $990K | — | Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |